RATIONALE: It has been suggested that hypothalamic-pituitary-adrenocortical (HPA) system dysregulation plays an important role in the pathophysiology of depression and that normalization of HPA axis hyperactivity precedes successful treatment with antidepressants. Mirtazapine acts as an antagonist at presynaptic alpha(2)-receptors and at postsynaptic 5-hydroxytryptamine (5-HT)(2), 5-HT(3) and histamine H(1) receptors. It has been shown acutely to inhibit cortisol secretion in healthy subjects. OBJECTIVE: In this study, we investigated whether mirtazapine may downtune HPA axis hyperactivity in depressed patients and whether this is related to treatment outcome. METHODS: Forty patients suffering from a major depressive episode (DSM-IV criteria) were treated with mirtazapine for 5 weeks. The combined dexamethasone suppression/CRH stimulation test (DEX/CRH test) was performed before and after 1 week of mirtazapine treatment (45 mg daily). RESULTS: Mirtazapine effectively reduced the overshoot of cortisol and ACTH during the DEX/CRH test both in treatment responders and non-responders within 1 week. CONCLUSIONS: Apparently, mirtazapine rapidly attenuates HPA axis hyperactivity in depressed patients via direct pharmacoendocrinological effects. However, this amelioration of HPA system dysregulation is not necessarily related to clinical improvement.
RATIONALE: It has been suggested that hypothalamic-pituitary-adrenocortical (HPA) system dysregulation plays an important role in the pathophysiology of depression and that normalization of HPA axis hyperactivity precedes successful treatment with antidepressants. Mirtazapine acts as an antagonist at presynaptic alpha(2)-receptors and at postsynaptic 5-hydroxytryptamine (5-HT)(2), 5-HT(3) and histamine H(1) receptors. It has been shown acutely to inhibit cortisol secretion in healthy subjects. OBJECTIVE: In this study, we investigated whether mirtazapine may downtune HPA axis hyperactivity in depressedpatients and whether this is related to treatment outcome. METHODS: Forty patients suffering from a major depressive episode (DSM-IV criteria) were treated with mirtazapine for 5 weeks. The combined dexamethasone suppression/CRH stimulation test (DEX/CRH test) was performed before and after 1 week of mirtazapine treatment (45 mg daily). RESULTS:Mirtazapine effectively reduced the overshoot of cortisol and ACTH during the DEX/CRH test both in treatment responders and non-responders within 1 week. CONCLUSIONS: Apparently, mirtazapine rapidly attenuates HPA axis hyperactivity in depressedpatients via direct pharmacoendocrinological effects. However, this amelioration of HPA system dysregulation is not necessarily related to clinical improvement.
Authors: P P Hubain; L Staner; M Dramaix; M Kerkhofs; G Papadimitriou; J Mendlewicz; P Linkowski Journal: Biol Psychiatry Date: 1998-02-01 Impact factor: 13.382
Authors: A M Ghadirian; F Engelsmann; V Dhar; D Filipini; R Keller; G Chouinard; B E Murphy Journal: Biol Psychiatry Date: 1995-03-15 Impact factor: 13.382
Authors: Cornelius Schüle; Thomas C Baghai; Daniela Eser; Peter Zwanzger; Martina Jordan; Renate Buechs; Rainer Rupprecht Journal: Psychopharmacology (Berl) Date: 2006-04-22 Impact factor: 4.530
Authors: Stefan Cohrs; Cornelia Röher; Wolfgang Jordan; Andreas Meier; Gerald Huether; Wolfgang Wuttke; Eckart Rüther; Andrea Rodenbeck Journal: Psychopharmacology (Berl) Date: 2006-01-24 Impact factor: 4.530
Authors: Georg Nikisch; Aleksander A Mathé; Adelheid Czernik; Jutta Thiele; Jürgen Bohner; Chin B Eap; Hans Agren; Pierre Baumann Journal: Psychopharmacology (Berl) Date: 2005-09-29 Impact factor: 4.530
Authors: Cornelius Schüle; Thomas C Baghai; Daniela Eser; Sibylle Häfner; Christoph Born; Sascha Herrmann; Rainer Rupprecht Journal: PLoS One Date: 2009-01-29 Impact factor: 3.240